ACP
ROIV icon

Acuta Capital Partners’s Roivant Sciences ROIV Stock Holding History

Acuta Capital Partners’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-220,000
Closed -$2.22M – 51
2023
Q2 		$2.22M Buy
+220,000
New +$1.97M 1.5% 22

Other funds holding ROIV

QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PSC
Patient Square Capital Menlo Park, California $564M AUM 261.3% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Acuta Capital Partners's ROIV Position: Q3 2023 in Review

Acuta Capital Partners sold out of Roivant Sciences (ROIV) in Q3 2023, closing a stake of 220,000 shares — an estimated $2.22M sold.

Acuta Capital Partners first reported a position in ROIV in Q2 2023 and held it in 1 quarter. The position peaked at $2.22M in Q2 2023. 205 funds tracked by Wall St. Rank hold ROIV as of Q3 2023.

  • Acuta Capital Partners reported no remaining Roivant Sciences position as of Q3 2023 after selling out during the quarter.
  • Acuta Capital Partners sold 220,000 Roivant Sciences shares in Q3 2023, an estimated $2.22M.
  • Acuta Capital Partners first reported a position in Roivant Sciences in Q2 2023 and held it in 1 quarter.
  • Acuta Capital Partners's Roivant Sciences position peaked at $2.22M in Q2 2023.
  • 205 funds tracked by Wall St. Rank held Roivant Sciences as of Q3 2023.

Based on Acuta Capital Partners's 13F filing for Q3 2023, filed 14 Nov 2023.